Please login to the form below

Not currently logged in
Email:
Password:

corticosteroid fluticasone furoate

This page shows the latest corticosteroid fluticasone furoate news and features for those working in and with pharma, biotech and healthcare.

GSK preps COPD filing for asthma pioneer Nucala

GSK preps COPD filing for asthma pioneer Nucala

Aside from Nucala, GSK is pinning its near-term hopes on dolutegravir-based HIV therapies and its closed triple therapy for COPD – delivering inhaled corticosteroid (ICS) fluticasone furoate, long-acting beta

Latest news

  • GSK files first application for triple COPD therapy GSK files first application for triple COPD therapy

    The therapy is a single device delivering inhaled corticosteroid (ICS) fluticasone furoate, long-acting beta agonist (LABA) vilanterol and long-acting muscarinic antagonist (LAMA) umeclidinium - covering the three most widely-used ... protect its

  • GSK's triple COPD therapy tops Symbicort in phase III trial GSK's triple COPD therapy tops Symbicort in phase III trial

    The phase III FULFIL trial compared the once-daily triple therapy - consisting of corticosteroid fluticasone furoate, long-acting muscarinic antagonist (LAMA) umeclidinium and long-acting beta agonist (LABA) vilanterol - to Symbicort, ... These include

  • GSK brings forward triple COPD therapy filing in US GSK brings forward triple COPD therapy filing in US

    The once-daily therapy developed by GSK and Innoviva (formerly Theravance) comprises corticosteroid fluticasone furoate, long-acting beta agonist (LABA) vilanterol and long-acting muscarinic antagonist (LAMA) umeclidinium - covering the three

  • FDA panel backs GSK's asthma drug Breo for adults only FDA panel backs GSK's asthma drug Breo for adults only

    The product is sold as Relvar in some markets and is a follow-up to GSK's blockbuster Seretide/Advair product and combines LABA vilanterol with the inhaled corticosteroid (ICS) fluticasone ... furoate. The FDA's panel of experts said the safety and

  • GSK trial throws everything at COPD GSK trial throws everything at COPD

    Tests combination of fluticasone furoate, umeclidinium and vilanterol. GlaxoSmithKline and partner Theravance have started a phase III trial of a triple therapy for chronic obstructive pulmonary disease (COPD) delivered using a ... The two companies will

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics